Merck (MRK) Other Operating Expenses (2010 - 2026)
Merck (MRK) reported Other Operating Expenses of $4.3 billion for Q1 2026, up 28.04% year-over-year from $3.4 billion in Q1 2025, and down 55.42% on a QoQ basis from $9.7 billion in Q4 2025.
Merck (MRK) has 17 years of Other Operating Expenses data on file, last reported at $4.3 billion in Q1 2026.
- Quarterly Other Operating Expenses rose 28.04% year-over-year to $4.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 billion (up 41.05% YoY) and the FY2025 annual result came in at $16.5 billion, up 8.99% from the prior year.
- Other Operating Expenses declined to $4.3 billion in Q1 2026 per MRK's latest filing, from $9.7 billion in the prior quarter.
- Across five years, Other Operating Expenses topped out at $9.7 billion in Q4 2025 and bottomed at $3.4 billion in Q1 2025.
- The 5-year median for Other Operating Expenses is $4.0 billion (2023), against an average of $4.7 billion.
- The widest annual swing landed in 2024, when Other Operating Expenses tumbled 51.28%; it then jumped 145.74% in 2025.
- Tracing MRK's Other Operating Expenses over 5 years: stood at $3.8 billion in 2022, then jumped by 113.27% to $8.1 billion in 2023, then tumbled by 51.28% to $4.0 billion in 2024, then jumped by 145.74% to $9.7 billion in 2025, then plunged by 55.42% to $4.3 billion in 2026.
- Per Business Quant, the three latest MRK Other Operating Expenses figures stand at $4.3 billion (Q1 2026), $9.7 billion (Q4 2025), and $3.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.33 Bn |
| Dec 31, 2025 | 9.72 Bn |
| Sep 30, 2025 | 3.62 Bn |
| Jun 30, 2025 | 3.55 Bn |
| Mar 31, 2025 | 3.38 Bn |
| Dec 31, 2024 | 3.96 Bn |
| Sep 30, 2024 | 3.92 Bn |
| Jun 30, 2024 | 3.79 Bn |
| Mar 31, 2024 | 3.51 Bn |
| Dec 31, 2023 | 8.12 Bn |
| Sep 30, 2023 | 4.39 Bn |
| Jun 30, 2023 | 4.20 Bn |
| Mar 31, 2023 | 4.02 Bn |
| Dec 31, 2022 | 3.81 Bn |
| Sep 30, 2022 | 4.36 Bn |
| Jun 30, 2022 | 4.65 Bn |
| Mar 31, 2022 | 6.09 Bn |
| Dec 31, 2021 | 3.54 Bn |
| Sep 30, 2021 | 3.00 Bn |
| Jun 30, 2021 | 3.00 Bn |
| Mar 31, 2021 | 2.74 Bn |
| Dec 31, 2020 | 4.78 Bn |
| Sep 30, 2020 | 5.43 Bn |
| Jun 30, 2020 | 2.36 Bn |
| Mar 31, 2020 | 3.38 Bn |
| Dec 31, 2019 | 1.34 Bn |
| Sep 30, 2019 | 4.03 Bn |
| Jun 30, 2019 | 3.54 Bn |
| Mar 31, 2019 | 3.24 Bn |
| Dec 31, 2018 | 3.40 Bn |
| Sep 30, 2018 | 3.45 Bn |
| Jun 30, 2018 | 3.37 Bn |
| Mar 31, 2018 | 4.69 Bn |
| Dec 31, 2017 | 3.29 Bn |
| Sep 30, 2017 | 3.10 Bn |
| Jun 30, 2017 | 3.04 Bn |
| Mar 31, 2017 | 2.98 Bn |
| Dec 31, 2016 | 3.57 Bn |
| Sep 30, 2016 | 3.43 Bn |
| Jun 30, 2016 | 3.60 Bn |
| Mar 31, 2016 | 3.62 Bn |
| Dec 31, 2015 | 4.75 Bn |
| Sep 30, 2015 | 3.59 Bn |
| Jun 30, 2015 | 4.49 Bn |
| Mar 31, 2015 | 3.62 Bn |
| Dec 31, 2014 | -6.89 Bn |
| Sep 30, 2014 | 4.06 Bn |
| Jun 30, 2014 | 4.24 Bn |
| Mar 31, 2014 | 3.74 Bn |
| Dec 31, 2013 | 4.71 Bn |
| Sep 30, 2013 | 4.17 Bn |
| Jun 30, 2013 | 4.37 Bn |
| Mar 31, 2013 | 4.11 Bn |
| Dec 31, 2012 | 4.60 Bn |
| Sep 30, 2012 | 4.18 Bn |
| Jun 30, 2012 | 4.07 Bn |
| Mar 31, 2012 | 4.07 Bn |
| Dec 31, 2011 | 4.06 Bn |
| Mar 31, 2011 | 500.00 Mn |
| Sep 30, 2010 | -950.00 Mn |